These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7563673)

  • 21. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects.
    Gaud U; Langer B; Petropoulou T; Thomas HC; Karayiannis P
    J Med Virol; 2003 Mar; 69(3):350-6. PubMed ID: 12526045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures.
    Shimizu YK; Igarashi H; Kiyohara T; Cabezon T; Farci P; Purcell RH; Yoshikura H
    Virology; 1996 Sep; 223(2):409-12. PubMed ID: 8806581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
    Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
    J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody.
    Taniguchi S; Okamoto H; Sakamoto M; Kojima M; Tsuda F; Tanaka T; Munekata E; Muchmore EE; Peterson DA; Mishiro S
    Virology; 1993 Jul; 195(1):297-301. PubMed ID: 7686313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
    Kronenberger B; Sarrazin C; Hofmann WP; von Wagner M; Herrmann E; Welsch C; Elez R; Rüster B; Piiper A; Zeuzem S
    J Viral Hepat; 2004 Jul; 11(4):310-8. PubMed ID: 15230853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV persistence and immune evasion in the absence of memory T cell help.
    Grakoui A; Shoukry NH; Woollard DJ; Han JH; Hanson HL; Ghrayeb J; Murthy KK; Rice CM; Walker CM
    Science; 2003 Oct; 302(5645):659-62. PubMed ID: 14576438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.
    Sherman KE; Andreatta C; O'Brien J; Gutierrez A; Harris R
    Hepatology; 1996 Apr; 23(4):688-94. PubMed ID: 8666318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation between viral fitness and immune escape within the hepatitis C virus protease.
    Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
    Gut; 2006 Feb; 55(2):266-74. PubMed ID: 16105887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus.
    Kato T; Mizokami M; Nakano T; Orito E; Ohba K; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Fujita K; Yasuda K; Iino S
    J Med Virol; 1998 Jun; 55(2):109-17. PubMed ID: 9598930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.
    Kato N; Ootsuyama Y; Sekiya H; Ohkoshi S; Nakazawa T; Hijikata M; Shimotohno K
    J Virol; 1994 Aug; 68(8):4776-84. PubMed ID: 7518526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2.
    Hu YW; Rocheleau L; Larke B; Chui L; Lee B; Ma M; Liu S; Omlin T; Pelchat M; Brown EG
    Virology; 2005 Feb; 332(2):538-49. PubMed ID: 15680419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation.
    Mondelli MU; Cerino A; Lisa A; Brambilla S; Segagni L; Cividini A; Bissolati M; Missale G; Bellati G; Meola A; Bruniercole B; Nicosia A; Galfrè G; Silini E
    Hepatology; 1999 Aug; 30(2):537-45. PubMed ID: 10421665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1.
    Sekiya H; Kato N; Ootsuyama Y; Nakazawa T; Yamauchi K; Shimotohno K
    Int J Cancer; 1994 Jun; 57(5):664-70. PubMed ID: 7515022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sequential analysis of the hypervariable region of the hepatitis C virus genome in acute infection].
    Asahina Y; Enomoto N; Kurosaki M; Sakuma I; Sato C
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):500-4. PubMed ID: 7563805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.